Core Viewpoint - Lifeward Ltd. is initiating a 1-for-12 reverse stock split to enhance its share price and comply with Nasdaq listing standards, effective February 24, 2026 [1][3]. Group 1: Reverse Split Details - The reverse split will convert every twelve issued and outstanding ordinary shares into one ordinary share, resulting in a decrease from approximately 18.3 million shares to about 1.5 million shares outstanding post-split [2][7]. - The Board of Directors has also approved an increase in the authorized share capital to 100,000,000 shares [2]. Group 2: Strategic Intent - The company believes that the reverse split will help meet Nasdaq's minimum bid price requirement of $1.00 per share, thereby maintaining its listing on the exchange [3]. - A new CUSIP number (M8216Q309) will be assigned to the ordinary shares, which will begin trading on a split-adjusted basis on the effective date [4]. Group 3: Impact on Securities - The reverse split will also apply to the company's outstanding warrants and stock options, with adjustments made to the number of shares and exercise prices accordingly [6]. - Fractional shares resulting from the reverse split will not be issued, and any fractional interests will be rounded down to the nearest whole number [5]. Group 4: Company Overview - Lifeward designs and commercializes innovative medical technology solutions aimed at improving the lives of individuals with physical limitations or disabilities [8]. - The company's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES Systems [8].

Core Insights - Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton, expanding access to approximately 16 million beneficiaries in the U.S. [1][2] Group 1: Company Developments - Lifeward Ltd. announced that Aetna issued prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, recognizing it as medically necessary for individuals with spinal cord injuries [1][2] - The ReWalk Personal Exoskeleton is an FDA-approved technology that enables individuals with spinal cord injuries to achieve functional ambulation, with multiple peer-reviewed studies supporting its benefits [2][3] Group 2: Market Impact - The recent approvals for prior authorization from three major Medicare Advantage insurers signify a significant advancement in access to exoskeletal rehabilitation technology for patients and providers [3][4] - A nurse with a spinal cord injury expressed that access to the ReWalk device represents a life-changing opportunity, emphasizing the importance of innovative mobility devices for dignity and independence [4] Group 3: Company Mission and Products - Lifeward is committed to driving innovation in medical technology to improve the lives of individuals with physical limitations or disabilities, with a product portfolio that includes the ReWalk Exoskeleton and other rehabilitation solutions [6][7]